41,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

The destruction of breast cancer cells by a phytochemical, Artonin E is a book for students, researchers and for all concerned with evidence-based therapeutic management of breast cancer using natural product. This research was borne out of a deep passion to subdue the global menace of breast cancer. The resistance and high toxicity ensuing from modern breast cancer treatment regimens have reduced the survival rate, causing most cancer patients to seek natural remedies with fewer side-effects as alternatives. Artonin E, is a naturally occurring prenylated flavonoid, reported to possess a wide…mehr

Produktbeschreibung
The destruction of breast cancer cells by a phytochemical, Artonin E is a book for students, researchers and for all concerned with evidence-based therapeutic management of breast cancer using natural product. This research was borne out of a deep passion to subdue the global menace of breast cancer. The resistance and high toxicity ensuing from modern breast cancer treatment regimens have reduced the survival rate, causing most cancer patients to seek natural remedies with fewer side-effects as alternatives. Artonin E, is a naturally occurring prenylated flavonoid, reported to possess a wide spectrum of in vitro biological activities. This book utilizes a rational approach in drug discovery and development to unravel the cancer inhibitory potential of this phytochemical, Artonin E. Embracing the advances in computational biology, it employed in silico models to predict the drug-likeness of this promising compound in comparison to similar analogues as well as its effect on the popular human estrogen receptor ¿ (hER ¿) which drives the majority of reported breast cancer cases. As reported herein, this compound is a promising sledge hammer needed to fight breast cancer.
Autorenporträt
The author, Dr. Imaobong Christopher Etti obtained her PhD in Pharmacology and Toxicology from the Universiti Putra Malaysia in 2017. Her research interest includes cancer chemotherapy, computational drug design, and molecular pharmacology. She has published, reviewed and edited many scientific writings, in contribution to knowledge in Pharmacology